Updated Phase III trial for the ABNCoV2 COVID-19 vaccine to include a licensed mRNA vaccine
Hørsholm, Denmark, June 16, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Bavarian Nordic’s upcoming Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been redesigned due to a licensed mRNA vaccine now being available as a comparator vaccine. This enables the design of a more robust double-blind, controlled study to demonstrate non-inferiority of ABNCoV2 to a licensed mRNA vaccine. The trial will be initiated in August, with data readout still expected in late 2022